Arrowhead Research | ARWR - Loan Capital


Arrowhead Research reported $1.23B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Ligand Pharmaceuticals USD 446.19M 702K Dec/2025
Merck USD 46.67B 77M Mar/2026
Moderna USD 603M 7M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Novartis USD 37.45B 7.86B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
TG Therapeutics USD 745.14M 499.5M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xencor USD 82.12M 5.64M Mar/2026